{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:54:17Z","timestamp":1793192057671,"version":"4.5.0"},"reference-count":10,"publisher":"S. Karger AG","issue":"6","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncology"],"published-print":{"date-parts":[[2021]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Background:&lt;\/i&gt;&lt;\/b&gt; Before the approval of first-line immune checkpoint inhibitors, platinum doublets were the standard of care in patients with treatment-na\u00efve advanced non-small cell lung cancer (NSCLC) without targetable driver mutations. Pemetrexed-platinum combinations are preferred in non-squamous NSCLC. However, there has been no direct comparison to paclitaxel-carboplatin. &lt;b&gt;&lt;i&gt;Methods:&lt;\/i&gt;&lt;\/b&gt; This open-label randomized trial was designed to compare pemetrexed-carboplatin with (weekly) paclitaxel-carboplatin in treatment-na\u00efve advanced\/metastatic non-squamous NSCLC without driver mutations. Patients received either pemetrexed 500 mg\/m&lt;sup&gt;2&lt;\/sup&gt; and carboplatin AUC 5 every 3 weeks, or paclitaxel 80 mg\/m&lt;sup&gt;2&lt;\/sup&gt; on day 1, day 8, and day 15 with carboplatin AUC 5 every 4 weeks for 4 cycles. Patients in both arms were allowed to receive pemetrexed maintenance. &lt;b&gt;&lt;i&gt;Results:&lt;\/i&gt;&lt;\/b&gt; A total of 180 patients were enrolled. The study was terminated early; however, at the time of analysis 75.8% of the required events had occurred. Finally, 164 patients were evaluable, 83 in the pemetrexed arm and 81 in the paclitaxel arm. After a median follow-up of 17 months, progression-free survival (PFS) rates at 6 months were not different in the two treatment arms (47.45 vs. 48.64%, &lt;i&gt;p&lt;\/i&gt; = 0.88). The median PFS values were 5.67 months (95% CI 3.73\u20137.3) and 5.03 months (95% CI 2.63\u20137.43) in each arm, respectively (HR 1.13, 95% CI 0.81\u20131.59, &lt;i&gt;p&lt;\/i&gt; = 0.44). The median overall survival was also not different: 14.83 months (95% CI 9.5\u201318.73) and 11.3 (95% CI 8.3\u201319.7; HR 1.19, 95% CI 0.8\u20131.78, &lt;i&gt;p&lt;\/i&gt; = 0.37). All grade toxicities were similar except for alopecia and peripheral neuropathy, which were higher in the paclitaxel arm. &lt;b&gt;&lt;i&gt;Conclusion:&lt;\/i&gt;&lt;\/b&gt; Pemetrexed-carboplatin is not superior to (weekly) paclitaxel-carboplatin as the first-line regimen in advanced non-squamous NSCLC in terms of PFS. <\/jats:p>","DOI":"10.1159\/000514577","type":"journal-article","created":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T21:08:48Z","timestamp":1617052128000},"page":"389-396","source":"Crossref","is-referenced-by-count":7,"title":["An Open-Label Randomized Controlled Trial Comparing the Efficacy and Safety of Pemetrexed-Carboplatin versus (Weekly) Paclitaxel-Carboplatin as First-Line Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer"],"prefix":"10.1159","volume":"99","author":[{"given":"Ajay","family":"Yadav","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0205-8559","authenticated-orcid":false,"given":"Prabhat Singh","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Khurana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepali","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreenivas","family":"Vishnubhatla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukesh","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushmita","family":"Pathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anant","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalit","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2021,3,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.0375"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70063-3"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2017.04.003"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.9114"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.9626"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000366"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.1912"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23583"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2019.04.005"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005"}],"container-title":["Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/514577","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/514577","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T16:26:12Z","timestamp":1745425572000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000514577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":10,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,5,27]]},"published-print":{"date-parts":[[2021,6,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000514577","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.14236835","asserted-by":"subject"}]},"ISSN":["0030-2414","1423-0232"],"issn-type":[{"value":"0030-2414","type":"print"},{"value":"1423-0232","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]}}}